J&J/Abiomed: healthcare giant pays high price to bulk up on medtech
EV/ebitda multiple is rich, given the healthcare giant expects any potential cost savings to be ‘very modest’
EV/ebitda multiple is rich, given the healthcare giant expects any potential cost savings to be ‘very modest’